These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 33263336

  • 1. Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.
    Kwak C, Nguyen QT, Kim J, Kim TH, Poo H.
    J Microbiol Biotechnol; 2021 Feb 28; 31(2):304-316. PubMed ID: 33263336
    [Abstract] [Full Text] [Related]

  • 2. Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
    Forqani M, Hosseini SM, Farahmand B, Saleh M, Shokouhi H, Torabi A, Fotouhi F.
    Biotechnol Lett; 2021 Nov 28; 43(11):2137-2147. PubMed ID: 34491470
    [Abstract] [Full Text] [Related]

  • 3. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H, Peng X, Jiao H, Zhao D, Ouyang J.
    Microb Cell Fact; 2015 Aug 05; 14():111. PubMed ID: 26242406
    [Abstract] [Full Text] [Related]

  • 4. Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.
    Nguyen QT, Kwak C, Lee WS, Kim J, Jeong J, Sung MH, Yang J, Poo H.
    Front Immunol; 2019 Aug 05; 10():1604. PubMed ID: 31354739
    [Abstract] [Full Text] [Related]

  • 5. Broadly Protective CD8+ T Cell Immunity to Highly Conserved Epitopes Elicited by Heat Shock Protein gp96-Adjuvanted Influenza Monovalent Split Vaccine.
    Zhang H, Zheng H, Guo P, Hu L, Wang Z, Wang J, Ju Y, Meng S.
    J Virol; 2021 May 24; 95(12):. PubMed ID: 33827939
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
    Shokouhi H, Farahmand B, Ghaemi A, Mazaheri V, Fotouhi F.
    Virus Res; 2018 Jun 02; 251():40-46. PubMed ID: 29730305
    [Abstract] [Full Text] [Related]

  • 7. Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Park BR, Subbiah J, Kim KH, Kwon YM, Oh J, Kim MC, Shin CH, Seong BL, Kang SM.
    Virology; 2022 Jan 02; 566():143-152. PubMed ID: 34929590
    [Abstract] [Full Text] [Related]

  • 8. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
    Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, Lanteigne AM, Hamelin ME, Mallett C, Papadopoulou B, Boivin G.
    Clin Vaccine Immunol; 2012 Feb 02; 19(2):209-18. PubMed ID: 22190392
    [Abstract] [Full Text] [Related]

  • 9. Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.
    Kim KH, Jung YJ, Lee Y, Park BR, Oh J, Lee YN, Kim MC, Jeeva S, Kang SM.
    Virology; 2020 Nov 02; 550():51-60. PubMed ID: 32882637
    [Abstract] [Full Text] [Related]

  • 10. Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses.
    Mytle N, Leyrer S, Inglefield JR, Harris AM, Hickey TE, Minang J, Lu H, Ma Z, Andersen H, Grubaugh ND, Guina T, Skiadopoulos MH, Lacy MJ.
    Viruses; 2021 Aug 27; 13(9):. PubMed ID: 34578289
    [Abstract] [Full Text] [Related]

  • 11. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W, Huang B, Wang X, Tan W, Ruan L.
    Virol Sin; 2019 Oct 27; 34(5):583-591. PubMed ID: 31240620
    [Abstract] [Full Text] [Related]

  • 12. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK, Chang S, Botham CM, Giffon TD, Fairman J, Lewis DB.
    J Virol; 2010 Dec 27; 84(24):12691-702. PubMed ID: 20943978
    [Abstract] [Full Text] [Related]

  • 13. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
    Ameghi A, Pilehvar-Soltanahmadi Y, Baradaran B, Barzegar A, Taghizadeh M, Zarghami N, Aghaiypour K.
    Viral Immunol; 2016 May 27; 29(4):228-34. PubMed ID: 27058011
    [Abstract] [Full Text] [Related]

  • 14. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A, Soleimanjahi H, Tavassoti Kheiri M, Jamali A, Mazaheri V, Abdollahpour Alitappeh M.
    Pathog Dis; 2014 Dec 27; 72(3):197-207. PubMed ID: 25066138
    [Abstract] [Full Text] [Related]

  • 15. A prime-boost vaccination of mice with heterologous H5N1 strains.
    Ikeno D, Kimachi K, Kudo Y, Goto S, Itamura S, Odagiri T, Tashiro M, Kino Y.
    Vaccine; 2009 May 18; 27(23):3121-5. PubMed ID: 19514127
    [Abstract] [Full Text] [Related]

  • 16. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA.
    J Virol; 2015 Mar 18; 89(6):3221-35. PubMed ID: 25568203
    [Abstract] [Full Text] [Related]

  • 17. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
    Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ.
    Influenza Other Respir Viruses; 2011 Nov 18; 5(6):426-37. PubMed ID: 21668670
    [Abstract] [Full Text] [Related]

  • 18. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
    Yam KK, Gupta J, Allen EK, Burt KR, Beaulieu É, Mallett CP, Burt DS, Ward BJ.
    Vaccine; 2016 Mar 14; 34(12):1444-51. PubMed ID: 26873056
    [Abstract] [Full Text] [Related]

  • 19. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X, Hu K, Shen M, Kong N, Fu C, Yan W, Wei A.
    J Virol Methods; 2016 Feb 14; 228():84-90. PubMed ID: 26615805
    [Abstract] [Full Text] [Related]

  • 20. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
    Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.
    Virol J; 2012 Dec 29; 9():322. PubMed ID: 23272943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.